CLINICAL_TRIALS
trial_result
· 2023-01-30
Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus [Phase 3]
Summary
Phase 3 trial of baricitinib in systemic lupus erythematosus was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: TERMINATED | Results posted: 2023-01-30